|Day Low/High||45.03 / 46.97|
|52 Wk Low/High||26.26 / 63.73|
Data show for the first time a systemic therapeutic effect in DMD dogs using a rAAV2/8 micro-dystrophin gene therapy approach without immunosuppressive treatment
This is pretty typical Fed Day action, when traders do some quick trades while they wait.
Sarepta Therapeutics, Inovio Pharmaceuticals and Mylan were among the biotech movers in premarket trading on July 20.
The MAP will be available to a limited number of patients who meet pre-specified medical criteria and can secure funding
Agreement terms resolve global patent proceedings regarding Sarepta's sale of EXONDYS 51® (eteplirsen) and future Duchenne muscular dystrophy (DMD) exon-skipping products
Akebia Therapeutics, Sarepta Therapeutics and Esperion Therapeutics were among the biotech stock movers in premarket trading on June 29.
Mr. Ingram was the President of Allergan, Inc.
The S&P 500 and Dow slip on a crude oil slump.
Stocks are mixed as energy lags, health care leads.
Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, is investigating Sarepta Therapeutics, Inc.
Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.
It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.